 TRACON Pharmaceuticals Inc NASDAQ:TCON has announced that the US Food and Drug Administration FDA has granted orphan drug designation to envafolimab, a novel, single-domain antibody against PD-L1. Envafolimab is the first subcutaneously injected PD-L1 inhibitor to be studied in pivotal trials. 